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Epithelial cell
B cellEpstein Barr virus (EBV) persists as a latent herpes virus infection in themajority of the adult human population.
The virus can reactivate from this latent infection into lytic replication for virus particle production. Here, we re-
port that autophagic membranes, which engulf cytoplasmic constituents during macroautophagy and transport
them to lysosomal degradation, are stabilized by lytic EBV replication in infected epithelial and B cells. Inhibition
of autophagicmembrane formation compromises infectious particle production and leads to the accumulation of
viral DNA in the cytosol. Vice versa, pharmacological stimulation of autophagic membrane formation enhances
infectious virus production. Atg8/LC3, an essential macroautophagy protein and substrate anchor on autophagic
membranes, was found in virus preparations, suggesting that EBV recruits Atg8/LC3 coupled membranes to its
envelope in the cytosol. Our data indicate that EBV subverts macroautophagy and uses autophagic membranes
for efﬁcient envelope acquisition during lytic infection.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Epstein Barr virus (EBV), a γ-herpes virus, is a remarkably successful
human pathogen with more than 95% of the entire adult human popu-
lation being infected (Rickinson et al., 2014). 50 years ago, EBVwas dis-
covered as the ﬁrst human tumor virus candidate in tissue samples of
Burkitt's lymphoma patients (Epstein et al., 1964). Cell-mediated im-
mune control is thought to keep persistent EBV infection in check and
prevent virus-associated malignancies. These malignancies harbor la-
tent EBV proteins, which drive cellular proliferation and survival in
order for EBV infected B cells to gain access to the memory B cell pool,related gene; BMRF1, BamH1M
ment leftward reading frame 1;
F1, BamH1A fragment leftward
g frame4;BRLF1,BamH1Rfrag-
ent rightward reading frame 1;
nt membrane protein 1; vFLIP,
munology, University of Zürich,
. This is an open access article underthe virus' site of persistence (Babcock et al., 1998; Kutok and Wang,
2006). EBV can reactivate from this memory B cell pool into lytic repli-
cation, and infectious particle production is initiated upon plasma cell
differentiation (Laichalk and Thorley-Lawson, 2005). The resulting vi-
rions are similar to those of other members of the herpes virus family.
EBV's double stranded DNA is encased by an icosahedral nucleocapsid,
sheltered by a protein tegument and ultimately surrounded by a viral
envelope decorated with viral glycoproteins (Johannsen et al., 2004).
A primary viral envelope is acquired after nucleocapsid assembly via
budding through the inner nuclear membrane. This ﬁrst envelope is
shed after fusion with the outer nuclear membrane, thereby releasing
the de-enveloped nucleocapsid into the cytosol. This nucleocapsid
acquires then its second and ﬁnal envelope in the cytosol. It is
thought that the membrane source of the ﬁnal herpes virus envelope
is perinuclear organelles like the trans-Golgi-network and often re-
quires virus induced organelle reorganization (Henaff et al., 2012).
The molecular machinery of macroautophagy can achieve such mem-
brane remodeling, and the second enveloping of EBV is topologically
reminiscent of macroautophagy. Indeed, α- and β-herpes virus infec-
tions are able to induce macroautophagy (English et al., 2009;
McFarlane et al., 2011), and herpes simplex virus (HSV) particles canthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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quirement of macroautophagy for the replication of these α- and β-
herpes viruses was reported so far.
Macroautophagy is a highly conserved major cytoplasmic degrada-
tion pathway of eukaryotic cells, which, in contrast to the ubiquitin–
proteasome system, can engulf protein aggregates and organelles in a
double-membrane vesicle. This so-called autophagosome fuses with
lysosomes in order to degrade its cargo (Mizushima et al., 2011). The
molecular machinery required for macroautophagy consists of more
than 30 autophagy-related gene (atg) products. Among these, Atg8 –
in mammalian macroautophagy studies mainly represented by its
LC3B ortholog – gets coupled to the autophagic membrane. Atg8/LC3
mediates membrane fusion events during vesicle formation and re-
cruits cargo via LC3-interacting region (LIR) containing proteins. The
ubiquitin-like membrane coupling of Atg8/LC3 to membranes is medi-
ated by the ligation complex of Atg12, Atg5 and Atg16. In this complex
the ubiquitin-like molecule Atg12 is covalently attached to Atg5 and
assembles with Atg16 to a protein shell cradling the emerging
autophagosome (Kaufmann et al., 2014). This complex is frequently
targeted to inhibit macroautophagy. All Atgs dissociate from the
outer membrane upon autophagosome completion to allow efﬁcient
fusion with lysosomes. Various organelles have been implicated as a
source of autophagic membranes, including endoplasmic reticulum,
Golgi apparatus, outer nuclear membrane, mitochondria and the
plasma membrane (Lamb et al., 2013). Therefore, Atgs can restructure
cellular membranes and might be involved in cytosolic enveloping of
herpes viruses.
Thus, the aim of this study was to investigate the role of
macroautophagy proteins during EBV replication. We demonstrate
that in the transition from latent to lytic EBV infection autophagic
membranes are stabilized. Inhibition of this accumulation compro-
mises infectious particle production and arrests viral DNA export
from the cytosol. Furthermore, Atg8/LC3-conjugated membranes
get incorporated into mature virions. These data suggest that EBV
uses Atg8/LC3-coupled membranes for cytosolic enveloping.
2. Results
2.1. Autophagic Membranes are Stabilized Upon Lytic EBV Replication
We used two cellular systems to investigate macroautophagy regu-
lation in the transition from latent to lytic EBV infection. One is based
on the Burkitt's lymphoma cell line Akata (Takada et al., 1991), and
was transfected with ratCD2–GFP under the early lytic BamH1 M frag-
ment rightward reading frame 1 (BMRF1) promotor (Ressing et al.,
2005). These AKBM cells initiate lytic EBV replication upon B cell recep-
tor (BCR) cross-linking, resulting in the expression of GFP and ratCD2 on
their surface (Supplementary Fig. 1). In order to study macroautophagy
during lytic replication, membrane conjugation of the autophagosome
marker Atg8/LC3 (LC3-II) (Klionsky et al., 2012) was monitored 20 h
post-ligation of the BCR on AKBM and on control AK31 (EBV-negative
and reporter construct transfected Akata cells) (Fig. 1A and C). Latent
AKBM cells showed moderate levels of LC3-II, which increase 4-fold
upon the induction of lytic EBV replication (Fig. 1B). In contrast to this
late up-regulation of macroautophagy (20 h post-induction), LC3-II
levels were lower than in the non-induced AKBM control at early time
points (6 h post-induction), indicating a blockade or reduction in au-
tophagy. These protein levels were marginally enhanced within 12 to
16 h, but after an incubation of 24 h, the LC3-II protein levels had
risen signiﬁcantly above the steady-state levels (Supplementary
Fig. 4A).When narrowing down the time frame of macroautophagy up-
regulation, at 13 h macroautophagy was still unaffected, whereas the
17-hour time point depicted a change in autophagy and the respective
up-regulation was even stronger when analyzing LC3-II protein levels
after 21 h (Supplementary Fig. 4B). In contrast, AK31 cells did not
show any alterations in endogenous LC3-II levels in response to theligation of surface IgG (Fig. 1C). Importantly, these cells also did not dis-
play any expression of the BamH1 Z fragment leftward reading frame 1
(BZLF1) protein upon cross-linking, verifying that these cells are indeed
EBV negative and do not enter lytic EBV replication,which is initiated by
BZLF1 (Fig. 1C). In addition, the production of human IL-10 into the su-
pernatant of IgG treated AKBM and AK31 veriﬁed successful BCR liga-
tion on both cell types (Supplementary Fig. 2). Up-regulation of LC3-II
expression can derive from increased macroautophagy, or from an
accumulation of autophagosomes. In order to distinguish these twopos-
sibilitieswe blocked lysosomal degradation of autophagosomes. Chloro-
quine is a lysosomotropic reagent elevating the pH within lysosomes
and therefore inhibits the degradation of autophagosomes. Upon treat-
mentwith chloroquine, LC3-II accumulation could be observed in latent
and lytic cells to the same levels, indicating that the detected upregula-
tion of LC3-II expression by lytic EBV replication was a result of a partial
block of autophagic membrane delivery to lysosomes (Fig. 1A). More-
over, using immunoﬂuorescence approaches, we observed that reacti-
vation to the lytic phase induced autophagosome accumulation in the
cytosol of AKBM cells (Supplementary Fig. 3). Therefore, EBV infected
B cells stabilize autophagic membranes upon lytic EBV reactivation.
In order to study another EBV infected cell type, we assessed alter-
ations in macroautophagy in the 293/EBV-wt epithelial cell line, which
harbors the recombinant EBV genome of the B95-8 strain and can be in-
duced to produce EBV particles via BZLF1 and BALF4 transfection
(Delecluse et al., 1998). In line with the results obtained in the AKBM
cell line, a 5.5-fold increase in LC3-II protein levels was observed in
transfected 293/EBV-wt cells compared to mock transfected cells
3 days post-induction (Fig. 1D and E). In both 293/EBV-wt and AKBM
cells lipidated LC3 accumulated after more than 20 h of lytic EBV cycle
induction (Supplementary Fig. 4C). Increased macroautophagy could
also be observed by the quantiﬁcation of LC3 puncta formation in the cy-
toplasm of BZLF1 positively stained, lytic 293/EBV-wt cells (Fig. 1F and
G). Additionally, LC3 punctae were already visible within 24 and 48 h
post-transfection in 293/EBV-wt cells (Supplementary Fig. 5). Thus,
these results suggest that lytic EBV replication leads to the accumulation
of autophagic membranes by partially blocking their degradation.
2.2. Macroautophagy Modulates the Production of Infectious EBV Particles
In order to investigate the inﬂuence ofmacroautophagy on EBVmat-
uration and viral particle production,we silencedmacroautophagy gene
expression via lentiviral shRNA constructs, targeting Atg12 and Atg16
in 293/EBV-wt cells. The Atg12–Atg5–Atg16 complex is essential for
autophagosome formation by ligating Atg8/LC3 to autophagosomal
membranes (Fujita et al., 2008; Hanada et al., 2007). Recombinant
B95-8 EBV production by293/EBV-wt cells could be quantiﬁed in subse-
quent titrations on Raji and Ramos cells, since this virus contains a GFP
reporter cassette, which gets rapidly expressed in infected cells and can
be quantiﬁed as Raji or Ramos green units (RGU). Atg12 and Atg16
silencing reduced the production of EBV particles from 293/EBV-wt
cells during lytic EBV infection by 60–80% in the supernatants as
assessed by Raji and Ramos titration (Fig. 2A, B and G). Notably, this
macroautophagy inhibition did not alter cell viability in transduced
cells compared to controls (Supplementary Fig. 6).
Furthermore, in line with these loss-of-function experiments,
we could observe the opposite effect for rapamycin-induced
macroautophagy during EBV production. Infectious particle production
was increased upon pharmacological macroautophagy stimulation
(Fig. 2E to G). Although rapamycin treatment enhanced virus production
and macroautophagy, concentration higher than 5 μM did not increase
virus production further (Fig. 2E and F), and might even overcome the
block of autophagosomematuration during lytic EBV infection, resulting
in virus degradation. The rapamycin induced enhanced infectious parti-
cle production was dependent on autophagic membrane formation, be-
cause Atg12 silencing abolished the rapamycin induced increase in
infectious EBV particle production (Fig. 2G). These gain- and loss-of-
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sists infectious EBV particle production.
2.3. Macroautophagy Inhibition Leads to an Accumulation of EBV DNA in
the Cytosol
In order to understand at which step autophagic membranes assist
lytic EBV replication, we investigated the intracellular distribution ofEBV particles by their DNA in 293/EBV-wt cells. Macroautophagy inhibi-
tion did not cause substantial differences in the total intracellular EBV
DNA as analyzed by real-time PCR (Fig. 3C, total). Hence, after cellular
fractionation we analyzed the different subcellular compartments for
their EBV DNA content. As expected, EBV copy numbers were highest
in the nuclear fraction, the site of viral DNA replication. Nevertheless,
we did not detect signiﬁcant differences in viral genome content in
the nuclear and vesicular fractions of 293/EBV-wt cells transfected
119H. Nowag et al. / EBioMedicine 1 (2014) 116–125with control versus macroautophagy silencing constructs (Fig. 3A to C).
In contrast, we could see a signiﬁcant increase in EBV DNA content in
the macroautophagy deﬁcient cytosolic fraction, when comparing to
the control transduced cells (Fig. 3A to C), indicating that EBV particles
accumulate in the cytosol uponmacroautophagy inhibition. These stud-
ies suggested that autophagic membranes might contribute to cytosolic
maturation of EBV.
2.4. LC3-II is Present in Puriﬁed EBV Viral Particles
Indeedwe could ﬁnd in transmission electronmicrographs cytosolic
viral capsids in lytically EBV replicating 293/EBV-wt cells that were
surrounded by two membranes, reminiscent of autophagosomes (Sup-
plementary Fig. 7). If these autophagic membranes would contribute to
cytosolic viral particle maturation by providing the second and the ﬁnal
envelope of EBV, then onewould have to postulate that Atg8/LC3,which
remains covalently coupled to the inner autophagosomal membrane,
could be found in puriﬁed viral particles. Therefore, we enriched recom-
binant EBV from supernatants of induced 293/EBV-wt cells by sequen-
tial centrifugation and blotted virus pellets against LC3 (Fig. 4A, P2,
and B). As controls, we used virus-depleted, ﬁltered supernatants and
non-induced 293/EBV-wt supernatants (Fig. 4A, P2+ and mock P2,
and B). Remarkably, we could detect high levels of the lipidated LC3-II,
but not free LC3-I in the virus pellet, whereas no LC3 was present in
the non-induced supernatants (Fig. 4A to D).
In order to exclude the co-puriﬁcation of LC3 containing vesicles of
similar density and size, we visualized LC3 on puriﬁed virus particles
by means of immunoelectron microscopy (Fig. 4G). For this purpose,
we precipitated EBV particles with anti-gp350 coated beads, which
enriched for morphologically identiﬁable virus particles (Fig. 4E) and
lipidated LC3 (Fig. 4F). Morphological analysis revealed that VLPs
(Fig. 4E, black arrows) and mature virions (Fig. 4E, white arrows) are
present in the precipitation of EBV. Immunogold-labeling of LC3 re-
vealed the presence of this label of autophagic membranes on virus
particles (Fig. 4G, black arrows), while no background could be ob-
served on the beads (asterisk) or membrane aggregates (Fig. 4G,
white arrows). Moreover, control rabbit antiserum did not label viral
particles (Fig. 4G, NRS control), and the LC3 speciﬁc antiserum signif-
icantly labeled enriched viral particles compared to rabbit control
serum (Fig. 4H). Thus, lipidated LC3-II seems to get incorporated
into EBV viruses during their maturation in the cytosol and these
data strongly indicate that autophagic membranes contribute to
the ﬁnal envelope of this ubiquitous human tumor virus.
3. Discussion
Our study demonstrates the incorporation of membranes that have
been modiﬁed by the macroautophagy machinery into virus particles.
This membrane reorganization seems to assist the envelope acquisition
of EBV in the cytosol, asmacroautophagy inhibition decreases infectious
particle production and accumulates EBV DNA in the cytosol. Therefore,
autophagic membrane stabilization, which we observed during the
induction of lytic EBV replication and could be further elevated via
rapamycin, augments EBV production.Fig. 1. Autophagic membrane accumulation in EBV producing cells. (A) Human AKBM cells we
levelswere assessed after 20 h byWestern blot. In parallel, 50 μMchloroquine (CQ)was supplem
II/β-actin ratio normalized to latent AKBM sample. Blot represents 12 individual experiments. (
levels in latent (−IgG) and lytic (+IgG) AKBM cells (n= 12). Data are expressed asmeans± S
with anti-human IgG F(ab)2 for 2 h. Atg8/LC3, BZLF1 and β-actin protein levels were examined
bation, in parallel. Asterisk denotes positive BZLF1 protein band of AKBMsample. Numbers below
Blot represents one of 3 individually performed experiments. (D) 293/EBV-wt cells were analyz
parallel, 50 μM chloroquine (CQ) was supplemented in the ﬁnal 6 h of incubation. Blot is repre
normalized to β-actin inmock and EBV-producing 293/EBV-wt cells (n= 10). Data are express
LC3 positive vesicles in BZLF1 expressing cells undergoing lytic EBVproduction versusmock 293
t test; ***, P b 0.001. Transfection efﬁcacy was at least 50% as assessed by BZLF1 positivity. (G
Staining for BZLF1 (white), Atg8/LC3 (red) and DAPI (blue), scale bar 10 μm. (DAPI, 4′,6-dWhile direct recruitment of autophagic membranes into virus parti-
cles has not been reported before, a number of viruses seem to target
the catabolic macroautophagy pathway. Indeed, only Sindbis virus has
been shown to be directly restricted bymacroautophagymediated deg-
radation (Orvedahl et al., 2011). Double-membrane vesicle accumula-
tion after poliovirus infection was already shown in 1965 (Dales et al.,
1965). This and other RNA viruses seem to replicate on membranes,
which they induce via the macroautophagy machinery (Dreux et al.,
2009; Jackson et al., 2005; Judith et al., 2013). Some also use the induced
vesicular compartments to leave their host cells, as has been proposed
for HIV replication in myeloid cells (Kyei et al., 2009). Such accumula-
tion of autophagic membranes can result from pathogen-induced inhi-
bition of autophagosome fusion with lysosomes. Such an accumulation
was shown for inﬂuenza A virus infection (Gannage et al., 2009), and
someof the enrichedAtg8/LC3 coupledmembranesmight be redirected
to the plasmamembrane for ﬁlamentous budding of stable virus par-
ticles (Beale et al., 2014). However, the utilization of autophagic
membranes has not been reported so far for DNA viruses. Indeed,
herpes viruses rather seem to encode Bcl-2 homologues that inhibit
autophagosome formation via their binding to Atg6/Beclin-1 (E et al.,
2009; Ku et al., 2008; Orvedahl et al., 2007; Pattingre et al., 2005). EBV
also encodes two Bcl-2 homologues, BamH1 H fragment rightward
reading frame 1 (BHRF1) and BamH1 A fragment leftward reading
frame 1 (BALF1), but their inﬂuence on macroautophagy has not been
reported (Altmann and Hammerschmidt, 2005). Nevertheless, they
could be responsible for the initial macroautophagy inhibition that we
observed early after lytic EBV replication induction in AKBM cells (Sup-
plementary Fig. 4A and B). In addition, viral FLICE-like inhibitor proteins
(vFLIPs) of herpes viruses seem to inhibit binding of Atg3 to Atg8/LC3,
thereby inhibiting the E2-like step of Atg8/LC3's ubiquitin-like conjuga-
tion to membranes (Lee et al., 2009). The human γ-herpes virus Kaposi
Sarcoma associated herpes virus (KSHV) encodes both amacroautophagy
inhibiting Bcl-2 and a Atg3 binding FLIP homologue (Lee et al., 2009;
Pattingre et al., 2005), but seems to increase macroautophagy after Rta
mediated reactivation of its lytic replication (Wen et al., 2010). In contrast
to the capacity of most herpes viruses to inhibit macroautophagy, the
other human γ-herpes virus EBV seems to utilize the molecular machin-
ery of macroautophagy. Along these lines, the latent membrane protein 1
(LMP1) of EBV seems to stimulate macroautophagy (Lee and Sugden,
2008). With this up-regulation LMP1 adjusts its expression levels via au-
tophagic LMP1 degradation. In the absence of this degradation regulation,
EBV transformed B cells undergo apoptosis due to high LMP1 expression.
Furthermore, it was recently shown that the immediate early lytic EBV
antigen BamH1 R segment leftward reading frame (BRLF1) up-regulates
macroautophagy (Hung et al., 2014). Moreover, lytic EBV replication in-
hibits autophagosome degradation to beneﬁt its own virus particle pro-
duction (Granato et al., 2014). In addition, we now demonstrate that
EBV stabilizes autophagic membranes during lytic infection and uses
these membranes for its envelope during cytosolic maturation. We
could demonstrate that Atg8/LC3-II is contained in supernatant fractions
of lytically EBV replicating cells similar in density and size to viral parti-
cles. Moreover, the precipitation of the EBV envelope protein gp350with
antibody-coupled beads enriched themain tegument protein BNRF1 and
Atg8/LC3-II compared to a control antibody. Finally immunoelectronmi-re incubated with anti-human IgG F(ab)2 fragments for 2 h. Atg8/LC3 and β-actin protein
entedduring theﬁnal 6 h of incubation. Numbers below blots indicate fold change of LC3
B) Densitometry quantiﬁcation of LC3-II bands normalized to their corresponding β-actin
D; paired t test; *, P b 0.05 on RU values of each blot. (C) HumanAK31 cells were incubated
20 h post-ligation by Western blot. 50 μM CQwas supplemented in the ﬁnal 6 h of incu
blot indicate fold change of LC3-II/β-actin ratio normalized to non-inducedAk31 sample
ed 3 days post-transfection for Atg8/LC3 and β-actin bymeans ofWestern blot analysis. In
senting one of 10 individual experiments. (E) Densitometry quantiﬁcation of LC3-II bands
ed as means± SD; paired t test; **, P b 0.01 on RU values of each blot. (F) Quantiﬁcation o
/EBV-wt cells. (n(mock) = 373; n(BZLF1+)= 369). Data expressed as median± SD
) Immunoﬂuorescence representations of 293/EBV-wt cells 3 days post-transfection
iamidino-2-phenylindole).-
-
.
f
;
.
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Fig. 3.Macroautophagy down-regulation traps viral DNA in the cytosol. (A) and (B) Subcellular fractionationwas performed on lytic 293/EBV-wt cells 3 days post-transfection, previously
transduced with Atg12 speciﬁc, shAtg16 speciﬁc or scramble shRNA. Fractions were obtained by differential sequential centrifugation and EBV episome copies were determined by RT-
qPCR. Viral copy number by BamH1W fragment speciﬁc PCR is shown for the individual fractions on top, while distribution of vesicular (Lamp2), nuclear (Lamin or Histone 4 (H4))
and cytosolic (Actin) marker proteins as assessed by Western blot analysis is shown on the bottom. Representative data for six independent experiments is shown. (C) Data of (A) and
(B) is expressed as ratio of viral loads of Atg16 or Atg12 speciﬁc shRNA to control (shScr) treated fractions. Scramble is set to 1. Statistics are performed onmean calculated copy numbers
from CT values of triplicates from six independent experiments. Data are expressed as mean ± SD, paired t test; *, P b 0.05.
121H. Nowag et al. / EBioMedicine 1 (2014) 116–125croscopy revealed the presence of Atg8/LC3 in herpes virus-like particles
in the supernatant of lytically EBV replicating cells. These ﬁve lines of ev-
idence suggest that EBV incorporates autophagic membranes into its
viral particles. Therefore, EBV seems to be a DNA virus that uses the
macroautophagy machinery for its replication.
However, leaving macroautophagy intact might render EBV vulner-
able to detection by adaptive T cell responses after antigen processingFig. 2.Modulation of macroautophagy in 293/EBV-wt cells inﬂuences the production of infec
(shAtg12) or control shRNA (shScr). Infectious EBV production was assessed in scramble ver
The results are representative of three independent experiments. (B) Quantiﬁcation of RGU/ml
(shScr). Data are expressed as means ± SD; paired t test; ***, P b 0.001 on RGU/ml in individu
(A and B) were tested by immunoblot, probing for LC3, Atg12–Atg5 complexes and β-actin o
(CQ)was supplemented in theﬁnal 6 h of incubation. Left: Atg12 silencing efﬁcacy assessed by A
normalized to β-actin below Atg12–Atg5 blot and ratio LC3-II/β-actin below LC3-II blot, Scramb
blot denote the quantiﬁcation of LC3-II protein levels normalized to β-actin, with scramble set
cated by numbers below the blot represents the fold increase of LC3-II compared tomock cells a
performed is shown (Rapa, rapamycin). (E) 293/EBV-wt cells were incubated with rapamycin (
tants of treated versus untreated lytic 293/EBV-wt cells 3 days post-transfection. Repre
(F) Quantiﬁcation of Raji titrations performed on varying concentrations of rapamycin treated
to lytic, untreated. Data expressed as means ± SD; paired t test on RGU numbers; *, P b 0.05, *
natants applied for each cell type. Data represents at least 3 independently performed assays avia macroautophagy (Münz, 2009). Indeed, the nuclear antigen 1 of
EBV (EBNA1) has been found to gain access toMHC class II presentation
intracellularly via macroautophagy (Leung et al., 2010; Paludan et al.,
2005). The resulting CD4+ T cell recognition leads to the elimination
of EBV transformed B cells in vitro (Long et al., 2005; Nikiforow et al.,
2003; Paludan et al., 2002). The underlying antigen processing path-
way seems to involve cytosolic engulfment of EBNA1 and fusion oftious EBV particles. (A) 293/EBV-wt cells were transduced with lentiviral atg12 speciﬁc
sus Atg12 speciﬁc shRNA expressing cells by Raji titration and is represented in RGU/ml.
in individual experiments. Data is represented in fold change in RGU normalized to control
al experiments (shAtg16, Atg16 speciﬁc shRNA). (C) Atg12 and Atg16 silencing levels for
n day 3 after transfection and quantiﬁed by densitometry. In parallel, 50 μM chloroquine
tg12–Atg5 complex, Atg5 and LC3-II protein levels. Quantiﬁcation of Atg12–Atg5 complex
le set to 1. Right: Atg16 silencing tested by immunoblot for LC3 and actin. Numbers below
to 1. (D) RepresentativeWestern blot for rapamycin treatment of (E). Quantiﬁcation indi-
fter normalization to the corresponding β-actin levels. One representative blot out of three
Rapa) 4 h prior to transfection. Raji titration was used to analyze EBV content in superna-
sentative Raji titration is shown and represents 5 independently performed assays.
293/EBV-wt cells. Data is expressed in fold change of rapamycin treated groups compared
*, P b 0.01 ***, P b 0.001. (G) Quantiﬁcation of Ramos and Raji titrations with same super-
nd is expressed as means ± SD.
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123H. Nowag et al. / EBioMedicine 1 (2014) 116–125autophagosomes with MHC class II loading compartments (MIICs),
which are primarily late endosomes equipped with the molecular
machinery for peptide generation and binding to MHC class II mole-
cules (Schmid et al., 2007). Consistent with EBV particles localizing
to autophagic membranes and then gaining access to MHC class II
loading is the ﬁnding that late lytic EBV antigens are frequently rec-
ognized by CD4+ T cells, while CD8+ T cell responses mainly focus on
immediate early and early lytic EBV antigens (Hislop et al., 2007).
While antigen release and up-take by neighboring latent EBV infect-
ed cells has been identiﬁed as one antigen processing pathway to
stimulate these late EBV antigen speciﬁc CD4+ T cells (Adhikary
et al., 2006), lytically EBV replicating cells might be recognized
directly via intracellular antigen processing onto MHC class II mole-
cules. Thus, usurping macroautophagy for cytosolic enveloping might
be a very efﬁcient strategy of EBV to acquire amembrane coat in the cy-
tosol, butmight also in part result in the presentation of its late lytic an-
tigens onto MHC class II molecules.
In summary, our study suggests that EBV uses Atg8/LC3-coupled
membranes to assemble its second envelope in the cytosol. This process
seems to be required for efﬁcient production and release of infectious
EBV particles. It represents an example of a human DNA virus directly
using the macroautophagy machinery to build its infectious particles
and to incorporate Atg8/LC3 coupled membranes into them.4. Material and Methods
4.1. Cell Culture
Akata cell subclones; EBV-positive AKBM and EBV-negative AK31
(Ressing et al., 2005) were cultured in R10 medium (RPMI + 10%
heat-inactivated FCS (PAA) + 50 U/ml penicillin/streptomycin);
AKBM cells were additionally grown in selection medium containing
hygromycin (300 μg/ml). Ligation of cell surface immunoglobulin
(IgG) was conducted by adding 25 μg/ml of goat-anti human anti-
F(ab′)2 IgG for 2 h, followed by the addition of fresh R10 in a total of
4× the initial volume and further incubation for 20 h at 37 °C, 5% CO2.
Cells considered for immunoblot analysis were either enriched popula-
tions viaMACS sorting or at least 70% GFP-positive. Sorting for lytic cells
was conducted by a mouse anti-ratCD2 speciﬁc antibody (OX34) and
then positively selected with goat anti-mouse IgG2a/b microbeads and
MS columns (Miltenyi). 293/EBV-wt cells were a generous gift from the
Delecluse lab (DKFZ, Heidelberg, Germany). Brieﬂy, these cells contain
the recombinant EBV strain B95-8 DNA as a bacmid under the selection
of hygromycin. Cells were cultured in D10 (DMEM + 10% heat-
inactivated FCS + 20 μg/ml gentamycin + 20 μg/ml hygromycin).
EBV production was triggered by transfection of 293/EBV-wt cells
with BZLF1 (p509) and BALF4 (p2670) plasmids. In brief, small-scale
experiments were conducted with 0.75 × 106 cells in a 6 cluster-well
plate with 0.5 μg of each plasmid and the metafectene (Biontex) mix
was incubated on cells for 3 h and replaced with 2 ml of fresh D10.
EBV viral supernatants were harvested 3 days post-transfection, if not
stated otherwise.Fig. 4. LC3-II is found in viral particles. (A) Supernatants obtained frommockand induced293/EBV-
steps. Total cell lysate (input), cellular debris (P1) and virus containing pellets (P2)were subjected
partwas furtherﬁltered through0.2 μmporeﬁlters to removeEBV (+)and the other partwas left u
(B) Two independently performed experiments with LC3 protein evaluation of P2 pellets byWest
level of six experiments (includingA andB). Statistics are performedon relative units (RU), paired t
is represented in fold change to EBV fraction for three performed experiments withmedian± SD,
particles precipitated with anti-gp350 antibody coupled beads. Mature virus particle (white arrow
analysis for Atg8/LC3 and BamH1 N fragment rightward reading frame 1 (BNRF1) viral tegument
cipitates that were obtained with isotype coupled beads as a control (isotype). Blot represents 3 i
bead precipitated virus, developed with gold particle coupled secondary antibodies recognizing A
ruses,white asterisk one antibody coupled bead andwhite arrows non-viralmembrane aggregates
bar = 200 nm. (H) Quantiﬁcation of gold particles per virus of (G) in LC3 stained versus NRS con4.2. Antibodies
For immunoblotting, anti-Atg8/LC3 (clone 5F10) and -Atg5 (clone
7C6)were purchased fromNanotools, Lamp2 (cloneH4B4) from South-
ern Biotech, mouse anti β-actin (clone AC-15) from Abcam and Lamin
A/C (clone H-110) from Santa Cruz Biotechnologies and antibody anti-
histone H4 (clone 62-141-13) was obtained fromMillipore. For immu-
noﬂuorescence stainings, rabbit anti-Atg8/LC3 was received fromMed-
ical Biological Laboratories, mouse anti-gp350 (clone 72A1, HB) from
hybridoma cells from ATCC, and mouse anti-BZLF1 (clone BZ-1) from
Santa Cruz Biotechnologies. Secondary antibodies conjugated with
Alexa Fluor 555 or Alexa Fluor 647 were purchased from Invitrogen.
Control rabbit polyclonal antiserum used for immunoprecipitation
was obtained from Novus Biological.
4.3. Lysate Preparation and Immunoblotting
In order to obtain protein extracts, cellswere collected at the indicat-
ed times, washed twice in PBS, resuspended in ice-cold lysis buffer (1%
NP-40 with complete protease inhibitor cocktail from Roche) and incu-
bated on ice for 10 min. The resulting cell lysates were centrifuged at
20,000 g for 10 min at 4 °C. For all samples, equal amounts of total pro-
tein extracts were boiled for 5min in the presence of SDS-PAGE loading
buffer NuPage (Life Technologies) with 1% β-mercaptoethanol. Protein
extracts were resolved in 12.5% SDS-PAGE gels and transferred onto
PVDF membranes (GE healthcare). For the detection of speciﬁc protein
bands, primary antibodies, HRP-conjugated secondary antibodies and
the ECL Plus detection systemswere used (Thermo Scientiﬁc). Quantiﬁ-
cation of protein levels by densitometry was performed on a Vilber
Lourmat Fusion FX imaging system or on digitalized ﬁlms using the
ImageJ software.
4.4. Quantitative PCR
Cellular DNA was extracted using QIAamp DNeasy blood and tissue
kit and viral DNA from culture supernatant was obtained with the
QIAamp minELUTE viral DNA kit (Quiagen). EBV DNA was quantiﬁed
by Taqman (Applied Biosystems) Real-time PCR with BamHI-W frag-
ment primers (Fw 5′-GGACCACTGCCCCTGGTATAA-3′; Rev 5′-TTTGTG
TGGACTCCTGGGG-3′; Probe 5′-(6FAM)-TCCTGCAGCTATTTCT GGTCGC
ATCA-(TAMRA)-3′) and was performed on a CFX384 Touch Real-Time
PCR Detection System (Bio-Rad). All samples were tested in triplicates,
and mean results were determined.
4.5. Immunoﬂuorescence
AKBM cells were centrifuged (500 g, 3 min) on poly-L-lysine coated
glass slides (Menzel-Gläser; 1.5 mm) and 293/EBV-wt cells were cul-
tured on poly-D-lysine coated round glass coverslips in a 12 well plate.
At the indicated time points, cells were ﬁxed in 3% PFA for 15 min at
4 °C. All subsequent steps were performed at room temperature and
all washes done with PBS supplemented with 1% ﬁsh skin gelatin and
0.02% saponin (Sigma). Cells were permeabilized with 0.1% Triton X-wtcellswereharvested after 3 days and subjected to puriﬁcation by sequential centrifugation
toWestern blot analysis for Atg8/LC3 and LaminA/C.Moreover, P2was resuspended and one
nﬁltered (−).Western blot results are representative of a total of six performedexperiments.
ern blot, with andwithout 0.2 μm ﬁltration. (C) Densitometry quantiﬁcation of LC3-II protein
test *, Pb 0.05. (D) Raji titration onﬁltered (+0.2 μm)andunﬁltered (EBV) P2 fractions. Data
paired t test on RGU/ml, ***, P b 0.001. (E) Transmission electron microscope picture of viral
) and capsid depleted virus like particles (black arrow). Scale bar 100 nm. (F) Western blot
protein of total cell lysate (input), anti-gp350 bead precipitated virus (anti-gp350) and pre-
ndividually performed experiments. (G) Immunoelectron microscopic picture of anti-gp350
tg8/LC3 speciﬁc antiserum (left, anti LC3). Black arrows indicate some of the precipitated vi-
. Two representative images are shown for the rabbit control serum(right, NRS control). Scale
trol. Data is represented as median by horizontal red line.
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Invitrogen), followed by staining with the indicated antibodies and
suitable secondary antibodies. Slides were counterstained with
DAPI and mounted with ProLong gold antifade reagent (Invitrogen).
Cells were visualized through a 63×, 1.4 NA oil immersion lens with
an inverted confocal laser-scanning microscope (SP5; Leica). Count-
ed cells are represented as dot plots with median values displayed as
a horizontal line.4.6. ShRNA Silencing Through Lentiviral Transduction
The shRNA expression plasmids pLKO.1-puromycin shRNA scramble
(5-TCCTAAGGTTAAGTCGCCCTCG-3) and atg16 (5-CAGGAAGCCAATCG
GCT TAAT−3) were gifts from the J. Tschopp lab (University of Lausanne,
Lausanne, Switzerland). The shRNA atg12 (5-CCAAGGACTCATTGACTT
CAT-3) was a gift from the F.V. Chisari lab (Scripps Research Institute, La
Jolla, USA). Production of lentiviral particles was performed as previously
described in Schmid et al. (2007). In brief, lentiviral vectors were co-
transfected with the helper plasmids pCMV_R8.91 and pMD.G into 293T
cells by calcium phosphate transfection. Cell culture supernatants
containing the recombinant viral particles were harvested on day 2
post-transfection, ﬁltered through a 0.22 μm pore ﬁlter, and frozen at
−80 °C. For silencing with shRNA recombinant constructs, 293/EBV-wt
cells were infected with the corresponding lentiviruses at an MOI of 5
and incubated for a total of 3 days. Cells were kept on selection medium
(puromycin 4 μg/ml) for 2 passages before being used in experiments.4.7. Electron Microscopy
EBV particles puriﬁed with anti-gp350 coated microspheres were
ﬁxed for 16h at room temperature (RT)with 3% formaldehyde followed
by 2 h 2.5% glutaraldehyde in 0.1 M NaPO4 (pH 7.4) and, subsequently,
with 1% OsO4 in 50mM sodium cacodylate buffer, pH 7.3 dehydrated in
an ethanol series and embedded into Epon (Catalys). Ultrathin sections
of 50 nm were contrasted with uranyl acetate and lead citrate. For
immunostaining EBV particles on anti-gp350 coated beads were ﬁxed
with 3% formaldehyde, 0.025% glutaraldehyde in 0.1 M NaPO4 (pH 7.4),
and after three washing steps in PBS embedded in 12% gelatin in 0.1 M
NaPO4 (pH 7.4). Small pieces were incubated for 16 h in 2.3 M sucrose
in 0.01 M NaPO4 (pH 7.4) and frozen in liquid nitrogen. Cryosections
were thawed and incubated after blocking with 0.5% BSA (Applichem),
0.15% gelatin (Sigma) in 0.1 M NaPO4 (pH 7.4; blocking buffer) using a
rabbit anti LC3 antibody (MBL) followed by a goat anti rabbit Gold
12 nm, both in blocking buffer. After postﬁxation with 0.5% glutaralde-
hyde in H2O and three times washing in H2O sections were contrasted
with 0.3% uranylacetate (Mallinkrodt), 1.8% methylcellulose in H2O at
4 °C. Sections were analyzed in a Tecnai Spirit transmission electron mi-
croscope (FEI) with an ORIUS CCD camera (Gatan).4.8. EBV Puriﬁcation
293/EBV-wt cells were transfected to produce EBV for 3 days, after
which the supernatant was collected and ﬁltered through a 0.45 μm
ﬁlter. To obtain an enriched EBV pellet, supernatants were spun at
30,000 g for 2 h at 4 °C. The supernatant was carefully removed and
the virus pellet was resuspended in 10 ml ice-cold PBS. This fraction
was equally split into 2 tubes, one part was further ﬁltered through a
0.2 μm ﬁlter, that retains EBV particles and the other left unﬁltered.
Both, 0.2 μm ﬁltered and unﬁltered supernatants, were further centri-
fuged at 30,000 g for 2 h at 4 °C and the resulting pellets were carefully
resuspended in 100 μl ice-cold PBS. These fractions were examined by
Raji titration (described below) for EBV content and their Atg8/LC3 pro-
tein levels were analyzed by Western blot.4.9. Infectious Unit Determination (RGU)
Viral titers were determined from supernatants of 293/EBV-wt cells
producing EBV throughout 3 days. In order to estimate infectious units
in supernatants of EBV producing cells, the supernatant was ﬁltered
through 0.45 μm ﬁlters and inoculated on Raji or Ramos cells (4 × 104)
for 48 h as indicated. Titrations were always performed in duplicates.
Cells were analyzed by ﬂow cytometry using a BD FACS Canto Flow
Cytometer and the FlowJo software. Dead cells were excluded through
Live/Dead staining (Invitrogen) andEBV infected Raji cellswere detected
in the GFP-positive gate.
4.10. Inhibitors, Chemicals
Chloroquine and rapamycin were purchased from Sigma. Chloro-
quine was applied at a concentration of 50 μM, 6 h prior to the harvest
of cells for Western blot. Rapamycin was applied 4 h prior to the
induction of EBV production in 293/EBV-wt cells at the indicated
concentrations.
4.11. Subcellular Fractionation
Cellswere rinsed off culture dishes 3 days post-transfectionwith ice-
cold PBS and washed twice. The resulting pellet was resuspended in
1 ml homogenization buffer (0.25 M sucrose, 1 mM EDTA, 20 mM
HEPES, protease inhibitor cocktail, pH 7.4) and mechanically lysed by
passing the extract 20 times through a 24 G needle. To obtain the vari-
ous fractions, the lysate was consecutively spun at 1000 g for 10 min,
3000 g for 10 min and 17,000 g for 15 min to obtain the nuclear, mito-
chondrial (discarded) and vesicular fraction, respectively. The remain-
ing supernatant contained the cytosolic portion. The resulting pellets
were resuspended in PBS and equally divided into 2 tubes and re-
pelleted. One part was subjected to Western blot analysis and the
other part was resuspended in 200 μl of PBS and subjected to DNA ex-
traction by QIAamp DNA extraction kit.
4.12. ELISA
For IL-10 detection, supernatants of AKBM and AK31 cells were har-
vested after 20 h. These were then added undiluted onto previously
coated 96-well ELISA plates (Nunc-Immuno MaxiSorp; Thermo Fisher
Scientiﬁc). Cytokines were then detected with the biotinylated speciﬁc
antibodies and streptavidin–HRP (human IL-10 kit, Mabtech, Sweden),
using the peroxidase substrate tetramethylbenzidine (Sigma). Recom-
binant human IL-10 (25–1000 pg/ml) was used as standard.
4.13. Cell Viability Assay
Cells were harvested at indicated time points, washed in PBS, resus-
pended in 1× binding buffer, and stainedwith 1 μl Annexin V (Biolegend)
per 50 μl staining volume. 1 μl 7-AAD (Biolegend) per 50 μl staining vol-
ume was added to evaluate dead cells. Samples were incubated for
30 min at 4 °C and analyzed by ﬂow cytometry on an LSR Fortessa ﬂow
cytometer (BD Biosciences). Annexin V was detected in the APC channel
and 7-AAD in the PerCP channel.
4.14. Statistical Analysis
Where indicated, paired t testswere performed using the Prism soft-
ware (version 5.0a; GraphPad Software).
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